Eric C. Haupt
Research Subjects
Research Interests
Eric C. Haupt has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Erin Elizabeth Hahn
Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California
6 shared publications - Ernest Shen
Department of Research and Evaluation Kaiser Permanente Southern California Pasadena California USA
4 shared publications - Aasthaa Bansal
Comparative Health Outcomes, Policy & Economics (CHOICE) Institute, University of Washington, Seattle, WA
3 shared publications - Huong Q. Nguyen
Kaiser Permanente Southern California, Pasadena, CA, USA
3 shared publications - Anne C. Kirchhoff
Huntsman Cancer Institute 7 , Salt Lake City, Utah
2 shared publications - Cecile. A. Laurent
Division of Research, Kaiser Permanente Northern California , Pleasanton, CA
2 shared publications
Latest Publications
- 11 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF9
Burden of Hospitalizations in Four Adolescent and Young Adult Cancer Survivor Populations in the United States, 2006 to 2020
Background: We describe hospitalization rates in adolescent and young adult (AYA) cancer survivors 2 to 5 years (Y2–Y5) from diagnosis. Methods: Observational study of AYA cancer survivors diagnosed 2006 to 2020 was conducted in two healthcare systems [Kaiser Permanente Southern California (KPSC; n = 7,889) and Kaiser Permanente Northern California (KPNC; n = 7,338)] and two states [California (47,302) and Utah (n = 7,935)]. Hospitalizations were ascertained from electronic health records and statewide administrative records and stratified into pregnancy-related and other indications. Hospitalization rates were calculated by cohort. We estimated patient factors associated with hospitalizations using a Poisson model. Results: Most AYA survivors were women (∼64% of all cohorts), with a mean age of ∼31 years at diagnosis, and were predominantly non-Hispanic White (range, 35.1%–81.2%) or Hispanic (range, 14.3%–40.6%). Overall, 21% to 24% of AYA survivors experienced ≥1 hospitalization. Unadjusted hospitalization rates declined from Y2 [range, 155.1–243.4 per 1,000 person-years (PY)] to Y5 (range, 105.8–132.0 PY; P trend < 0.0001 in all cohorts). Factors associated with increased non–pregnancy-related hospitalizations were [range of relative risks (RR)] non-Hispanic Black race/ethnicity (RR, 1.46–1.66 vs. non-Hispanic White); public insurance (RR, 1.57–1.93 vs. commercial/military); receipt of chemotherapy (RR, 1.51–1.81); and cancer type—breast cancer (RR, 1.69–1.97), cervical cancer (RR, 2.30–3.31), colorectal cancer (RR, 2.76–3.66), acute lymphoblastic leukemia (ALL; RR, 2.89–5.19), acute myeloid leukemia (AML; RR, 2.11–5.05), and sarcoma (RR, 2.70–4.96; all vs. thyroid). Conclusions: Although hospitalizations decline as the time from diagnosis elapses across health system settings and states, nearly one in five AYA cancer survivors experience hospitalization in early survivorship. Impact: Hospitalization rates remain elevated in some AYA patient subgroups in early survivorship, highlighting the need to identify AYAs at risk to mitigate unanticipated hospitalizations and costs.
- 11 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF9
Burden of Hospitalizations in Four Adolescent and Young Adult Cancer Survivor Populations in the United States, 2006 to 2020
Background: We describe hospitalization rates in adolescent and young adult (AYA) cancer survivors 2 to 5 years (Y2–Y5) from diagnosis. Methods: Observational study of AYA cancer survivors diagnosed 2006 to 2020 was conducted in two healthcare systems [Kaiser Permanente Southern California (KPSC; n = 7,889) and Kaiser Permanente Northern California (KPNC; n = 7,338)] and two states [California (47,302) and Utah (n = 7,935)]. Hospitalizations were ascertained from electronic health records and statewide administrative records and stratified into pregnancy-related and other indications. Hospitalization rates were calculated by cohort. We estimated patient factors associated with hospitalizations using a Poisson model. Results: Most AYA survivors were women (∼64% of all cohorts), with a mean age of ∼31 years at diagnosis, and were predominantly non-Hispanic White (range, 35.1%–81.2%) or Hispanic (range, 14.3%–40.6%). Overall, 21% to 24% of AYA survivors experienced ≥1 hospitalization. Unadjusted hospitalization rates declined from Y2 [range, 155.1–243.4 per 1,000 person-years (PY)] to Y5 (range, 105.8–132.0 PY; P trend < 0.0001 in all cohorts). Factors associated with increased non–pregnancy-related hospitalizations were [range of relative risks (RR)] non-Hispanic Black race/ethnicity (RR, 1.46–1.66 vs. non-Hispanic White); public insurance (RR, 1.57–1.93 vs. commercial/military); receipt of chemotherapy (RR, 1.51–1.81); and cancer type—breast cancer (RR, 1.69–1.97), cervical cancer (RR, 2.30–3.31), colorectal cancer (RR, 2.76–3.66), acute lymphoblastic leukemia (ALL; RR, 2.89–5.19), acute myeloid leukemia (AML; RR, 2.11–5.05), and sarcoma (RR, 2.70–4.96; all vs. thyroid). Conclusions: Although hospitalizations decline as the time from diagnosis elapses across health system settings and states, nearly one in five AYA cancer survivors experience hospitalization in early survivorship. Impact: Hospitalization rates remain elevated in some AYA patient subgroups in early survivorship, highlighting the need to identify AYAs at risk to mitigate unanticipated hospitalizations and costs.
- 1 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (5) , 780-792
Transitions Within and Use of Outpatient Primary and Oncology Care in Survivors of Adolescent and Young Adult-Onset Cancers
PURPOSE: Survivors of adolescent and young adult (AYA)-onset cancers require comprehensive cancer surveillance care. Guidelines recommend 1-4 clinician visits annually for 5 years depending on stage and disease. The goal of this study was to identify factors associated with patterns of post-treatment primary and oncology care in a large cohort of survivors of AYA-onset cancers diagnosed within an integrated health care system. METHODS: Patients diagnosed with cancer between 2006 and 2020 age 15-39 years were included. Surveillance visits were identified from electronic medical records 2-5 years after diagnosis. Multivariable logistic regression was used to assess associations with zero oncology specialty visits. RESULTS: Of 7,925 survivors, 46% were Hispanic, 6% non-Hispanic Black, 11% non-Hispanic Asian, 35% non-Hispanic White, and 65% female. One-quarter had no oncology specialty visits in the first surveillance year rising to 38% in year 5; 31% had 3+ visits in the first year, declining to 13% in year 5. Over the surveillance period, 17% did not have any oncology specialty visits and 6% had no primary care or oncology visits. Those who were male (odds ratio [OR], 1.21 [95% CI, 1.02 to 1.45]), 20-24 years at diagnosis (OR, 1.58, 95% CI, 1.27 to 1.9; v 35 to 39), or non-Hispanic Black (OR, 1.38, 95% CI, 1.05 to 1.82; v non-Hispanic White) or had high-deductible commercial or Medicaid insurance (OR, 1.35, 95% CI, 1.15 to 1.59; OR, 1.42, 95% CI, 1.11 to 1.82, respectively; v no or low deductible commercial) were more likely to be in the 0-visit group for oncology specialty care. CONCLUSION: Although the majority of this cohort received either primary or oncology specialty care, our study identifies those who may need tailored outreach for follow-up care. Continued research into development and testing of interventions to improve uptake of appropriate health care for survivors of AYA-onset cancers is critical.
- 1 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (5) , 780-792
Transitions Within and Use of Outpatient Primary and Oncology Care in Survivors of Adolescent and Young Adult-Onset Cancers
PURPOSE: Survivors of adolescent and young adult (AYA)-onset cancers require comprehensive cancer surveillance care. Guidelines recommend 1-4 clinician visits annually for 5 years depending on stage and disease. The goal of this study was to identify factors associated with patterns of post-treatment primary and oncology care in a large cohort of survivors of AYA-onset cancers diagnosed within an integrated health care system. METHODS: Patients diagnosed with cancer between 2006 and 2020 age 15-39 years were included. Surveillance visits were identified from electronic medical records 2-5 years after diagnosis. Multivariable logistic regression was used to assess associations with zero oncology specialty visits. RESULTS: Of 7,925 survivors, 46% were Hispanic, 6% non-Hispanic Black, 11% non-Hispanic Asian, 35% non-Hispanic White, and 65% female. One-quarter had no oncology specialty visits in the first surveillance year rising to 38% in year 5; 31% had 3+ visits in the first year, declining to 13% in year 5. Over the surveillance period, 17% did not have any oncology specialty visits and 6% had no primary care or oncology visits. Those who were male (odds ratio [OR], 1.21 [95% CI, 1.02 to 1.45]), 20-24 years at diagnosis (OR, 1.58, 95% CI, 1.27 to 1.9; v 35 to 39), or non-Hispanic Black (OR, 1.38, 95% CI, 1.05 to 1.82; v non-Hispanic White) or had high-deductible commercial or Medicaid insurance (OR, 1.35, 95% CI, 1.15 to 1.59; OR, 1.42, 95% CI, 1.11 to 1.82, respectively; v no or low deductible commercial) were more likely to be in the 0-visit group for oncology specialty care. CONCLUSION: Although the majority of this cohort received either primary or oncology specialty care, our study identifies those who may need tailored outreach for follow-up care. Continued research into development and testing of interventions to improve uptake of appropriate health care for survivors of AYA-onset cancers is critical.
- 1 July 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2500003
Using Early Biomarker Change and Treatment Adherence to Predict Risk of Relapse Among Patients With Chronic Myeloid Leukemia Who Are in Remission
PURPOSE: There is little guidance for decision making in chronic myeloid leukemia (CML) after patients achieve molecular remission. Our study addresses this gap by developing a risk prediction model for molecular relapse using early longitudinal factors, such as BCR::ABL1 biomarker-level changes and treatment adherence. METHODS: We analyzed electronic health record data of patients with CML diagnosed between 2007 and 2019 from an integrated health system. We used a time-to-event modeling framework using a Cox proportional hazards approach where we evaluated time from molecular remission to molecular relapse. The main predictors were early changes in BCR::ABL1 levels from treatment initiation to the first follow-up measurement (typically around 3 months) and treatment adherence in the first 6 months, categorized as perfect (≥0.98) or less-than-perfect (<0.98). Model performance was assessed through five-fold cross-validation combined with 100 Monte Carlo bootstrapping iterations to ensure robustness and minimize bias. RESULTS: Patients with early improvement in BCR::ABL1 levels had a 70% lower risk relapse (hazard ratio [HR], 0.30 [95% CI, 0.15 to 0.59]) compared with those without early molecular response. Perfect adherence during this critical early phase of treatment was associated with a 56% lower relapse risk (HR, 0.44 [95% CI, 0.22 to 0.85]). Predictive accuracy was high at 6 months (AUC, 0.90; 95% CI, 0.87 to 0.95) and 1-year postremission (AUC, 0.78; 95% CI, 0.74 to 0.81). Relapse risk was significantly higher among Black, Asian, and Hispanic patients compared with non-Hispanic White patients. CONCLUSION: Early biomarker trends and adherence after treatment initiation are critical for accurately predicting relapse among patients who achieve molecular remission. The proposed model addresses a gap in guidance after molecular remission and has the potential to enable personalized monitoring and optimize surveillance strategies, offering transformative potential for CML care.
- 1 July 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2500003
Using Early Biomarker Change and Treatment Adherence to Predict Risk of Relapse Among Patients With Chronic Myeloid Leukemia Who Are in Remission
PURPOSE: There is little guidance for decision making in chronic myeloid leukemia (CML) after patients achieve molecular remission. Our study addresses this gap by developing a risk prediction model for molecular relapse using early longitudinal factors, such as BCR::ABL1 biomarker-level changes and treatment adherence. METHODS: We analyzed electronic health record data of patients with CML diagnosed between 2007 and 2019 from an integrated health system. We used a time-to-event modeling framework using a Cox proportional hazards approach where we evaluated time from molecular remission to molecular relapse. The main predictors were early changes in BCR::ABL1 levels from treatment initiation to the first follow-up measurement (typically around 3 months) and treatment adherence in the first 6 months, categorized as perfect (≥0.98) or less-than-perfect (<0.98). Model performance was assessed through five-fold cross-validation combined with 100 Monte Carlo bootstrapping iterations to ensure robustness and minimize bias. RESULTS: Patients with early improvement in BCR::ABL1 levels had a 70% lower risk relapse (hazard ratio [HR], 0.30 [95% CI, 0.15 to 0.59]) compared with those without early molecular response. Perfect adherence during this critical early phase of treatment was associated with a 56% lower relapse risk (HR, 0.44 [95% CI, 0.22 to 0.85]). Predictive accuracy was high at 6 months (AUC, 0.90; 95% CI, 0.87 to 0.95) and 1-year postremission (AUC, 0.78; 95% CI, 0.74 to 0.81). Relapse risk was significantly higher among Black, Asian, and Hispanic patients compared with non-Hispanic White patients. CONCLUSION: Early biomarker trends and adherence after treatment initiation are critical for accurately predicting relapse among patients who achieve molecular remission. The proposed model addresses a gap in guidance after molecular remission and has the potential to enable personalized monitoring and optimize surveillance strategies, offering transformative potential for CML care.
- 1 September 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 7 (7) , e2300066
Using Machine Learning to Leverage Biomarker Change and Predict Colorectal Cancer Recurrence
Using machine learning to leverage CEA biomarker change and predict colorectal cancer recurrence.
- 1 September 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 7 (7) , e2300066
Using Machine Learning to Leverage Biomarker Change and Predict Colorectal Cancer Recurrence
Using machine learning to leverage CEA biomarker change and predict colorectal cancer recurrence.
- 1 June 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 7 (7) , e2300004
Racial Disparities in the Ascertainment of Cancer Recurrence in Electronic Health Records
PURPOSE: There is growing interest in using computable phenotypes or proxies to identify important clinical outcomes, such as cancer recurrence, in rich electronic health records data. However, the race/ethnicity-specific accuracies of these proxies remain unclear. We examined whether the accuracy of a proxy for colorectal cancer (CRC) recurrence differed by race/ethnicity and the possible mechanisms that drove the differences. METHODS: Using data from a large integrated health care system, we identified a stratified random sample of 282 Black/African American (AA), Hispanic, and non-Hispanic White (NHW) patients with CRC who received primary treatment. Patient 5-year recurrence status was estimated using a utilization-based proxy and evaluated against the true recurrence status obtained using detailed chart review and by race/ethnicity. We used covariate-adjusted probit regression models to estimate the associations between race/ethnicity and misclassification. RESULTS: The recurrence proxy had excellent overall accuracy (positive predictive value [PPV] 89.4%; negative predictive value 96.5%; mean difference in timing 1.96 months); however, accuracy varied by race/ethnicity. Compared with NHW patients, PPV was 14.9% lower (95% CI, 2.53 to 28.6) among Hispanic patients and 4.3% lower (95% CI, −4.8 to 14.8) among Black/AA patients. The proxy disproportionately inflated the 5-year recurrence incidence for Hispanic patients by 10.6% (95% CI, 4.2 to 18.2). Compared with NHW patients, proxy recurrences for Hispanic patients were almost three times as likely to have been misclassified as positive (adjusted risk ratio 2.91 [95% CI, 1.21 to 8.31]). Higher false positives among racial/ethnic minorities may be related to higher prevalence of noncancerous lung-related problems and substantial delays in primary treatment because of insufficient patient-provider communication and abnormal treatment patterns. CONCLUSION: Using a proxy with worse accuracy among racial/ethnic minority patients to estimate population health may misdirect resources and support erroneous conclusions around treatment benefit for these patients.
- 1 June 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 7 (7) , e2300004
Racial Disparities in the Ascertainment of Cancer Recurrence in Electronic Health Records
PURPOSE: There is growing interest in using computable phenotypes or proxies to identify important clinical outcomes, such as cancer recurrence, in rich electronic health records data. However, the race/ethnicity-specific accuracies of these proxies remain unclear. We examined whether the accuracy of a proxy for colorectal cancer (CRC) recurrence differed by race/ethnicity and the possible mechanisms that drove the differences. METHODS: Using data from a large integrated health care system, we identified a stratified random sample of 282 Black/African American (AA), Hispanic, and non-Hispanic White (NHW) patients with CRC who received primary treatment. Patient 5-year recurrence status was estimated using a utilization-based proxy and evaluated against the true recurrence status obtained using detailed chart review and by race/ethnicity. We used covariate-adjusted probit regression models to estimate the associations between race/ethnicity and misclassification. RESULTS: The recurrence proxy had excellent overall accuracy (positive predictive value [PPV] 89.4%; negative predictive value 96.5%; mean difference in timing 1.96 months); however, accuracy varied by race/ethnicity. Compared with NHW patients, PPV was 14.9% lower (95% CI, 2.53 to 28.6) among Hispanic patients and 4.3% lower (95% CI, −4.8 to 14.8) among Black/AA patients. The proxy disproportionately inflated the 5-year recurrence incidence for Hispanic patients by 10.6% (95% CI, 4.2 to 18.2). Compared with NHW patients, proxy recurrences for Hispanic patients were almost three times as likely to have been misclassified as positive (adjusted risk ratio 2.91 [95% CI, 1.21 to 8.31]). Higher false positives among racial/ethnic minorities may be related to higher prevalence of noncancerous lung-related problems and substantial delays in primary treatment because of insufficient patient-provider communication and abnormal treatment patterns. CONCLUSION: Using a proxy with worse accuracy among racial/ethnic minority patients to estimate population health may misdirect resources and support erroneous conclusions around treatment benefit for these patients.
- 1 October 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (28_suppl) , 36
Real-world risk-stratified cancer survivorship pathways.
36 Background: Risk-stratified survivorship care pathways are critical for meeting needs of cancer survivors and the oncology workforce. To support a clinical trial evaluating a survivorship model that transitions low-risk survivors to a primary care physician (PCP)-led survivorship clinic within an integrated healthcare system, we captured data on real-time clinical risk stratification of low-risk patients potentially eligible between 6 and 36 months after treatment cessation. Methods: After oncology stakeholder input, we developed a screening algorithm to identify low-risk breast and colorectal cancer (CRC) survivors from the electronic medical record based on data from pathology, treatment, and utilization records. The algorithm identified patients meeting study eligibility criteria: adult stage 0-IIb breast cancer or stage I-II CRC patients diagnosed with first primary cancer, excluding those with treatments indicative of high-risk or metastatic disease, ongoing ovarian suppression or trastuzumab treatment (breast), neoadjuvant chemotherapy (breast), or enrollment in other cancer clinical trials. Next, the treating oncologist was asked to confirm or deny patient eligibility based on low-risk criteria; if denied, ineligibility reason was requested. Characteristics and proportions of low-risk patients confirmed/denied eligibility and reasons for ineligibility are summarized. Results: 530 patients were identified and evaluated: 488 breast and 42 CRC. Mean age was 61 years (SD: 11.6, range 23-95); 96% female; 22% had stage 0 disease (breast only), 51% stage I, and 28% stage II. By cancer type, 390 breast patients were deemed eligible (80%); 31 CRC patients were eligible (74%). A greater proportion of Asian and Black patients were categorized eligible vs. ineligible (13% vs. 9%, and 25% vs.14%, respectively), and a smaller proportion of Hispanic and White were categorized eligible (26% vs. 33%, and 31% vs. 42%, respectively). Reasons for ineligibility included: suspicious for recurrence (6%), new primary disease (3%), complex case/condition (36%), patient preference (34%), and other/none (22%). “Complex case/condition” included reasons such as intolerance of chemotherapy, patient declined chemotherapy and/or endocrine treatment (breast), co-occurring hematology disorder; “other/none” included reasons such as current pregnancy Lynch syndrome, and no reason. Conclusions: Oncologists confirmed eligibility for 80% of algorithm-identified low-risk patients for referral to the PCP-led survivorship clinic. Of those ineligible, patient preference and complex case/condition were the most common reasons reported for ineligibility. Consensus-based risk algorithms supported by clinician review can quickly and effectively perform case identification of low-risk patients who may be appropriately transitioned to other settings for survivorship care.
- 1 October 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (28_suppl) , 36
Real-world risk-stratified cancer survivorship pathways.
36 Background: Risk-stratified survivorship care pathways are critical for meeting needs of cancer survivors and the oncology workforce. To support a clinical trial evaluating a survivorship model that transitions low-risk survivors to a primary care physician (PCP)-led survivorship clinic within an integrated healthcare system, we captured data on real-time clinical risk stratification of low-risk patients potentially eligible between 6 and 36 months after treatment cessation. Methods: After oncology stakeholder input, we developed a screening algorithm to identify low-risk breast and colorectal cancer (CRC) survivors from the electronic medical record based on data from pathology, treatment, and utilization records. The algorithm identified patients meeting study eligibility criteria: adult stage 0-IIb breast cancer or stage I-II CRC patients diagnosed with first primary cancer, excluding those with treatments indicative of high-risk or metastatic disease, ongoing ovarian suppression or trastuzumab treatment (breast), neoadjuvant chemotherapy (breast), or enrollment in other cancer clinical trials. Next, the treating oncologist was asked to confirm or deny patient eligibility based on low-risk criteria; if denied, ineligibility reason was requested. Characteristics and proportions of low-risk patients confirmed/denied eligibility and reasons for ineligibility are summarized. Results: 530 patients were identified and evaluated: 488 breast and 42 CRC. Mean age was 61 years (SD: 11.6, range 23-95); 96% female; 22% had stage 0 disease (breast only), 51% stage I, and 28% stage II. By cancer type, 390 breast patients were deemed eligible (80%); 31 CRC patients were eligible (74%). A greater proportion of Asian and Black patients were categorized eligible vs. ineligible (13% vs. 9%, and 25% vs.14%, respectively), and a smaller proportion of Hispanic and White were categorized eligible (26% vs. 33%, and 31% vs. 42%, respectively). Reasons for ineligibility included: suspicious for recurrence (6%), new primary disease (3%), complex case/condition (36%), patient preference (34%), and other/none (22%). “Complex case/condition” included reasons such as intolerance of chemotherapy, patient declined chemotherapy and/or endocrine treatment (breast), co-occurring hematology disorder; “other/none” included reasons such as current pregnancy Lynch syndrome, and no reason. Conclusions: Oncologists confirmed eligibility for 80% of algorithm-identified low-risk patients for referral to the PCP-led survivorship clinic. Of those ineligible, patient preference and complex case/condition were the most common reasons reported for ineligibility. Consensus-based risk algorithms supported by clinician review can quickly and effectively perform case identification of low-risk patients who may be appropriately transitioned to other settings for survivorship care.
- 30 March 2022
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 25 (4) , 620-627
Performance of Patient-Reported Outcome Measures in a Large Pragmatic Trial of Home-Based Palliative Care (HomePal): Methodological and Practical Considerations for Embedded Patient-Centered Design
Background: The research enterprise has embraced patient centeredness in embedded efficient pragmatic trials, but limited data exist on using patient-reported outcomes (PROs) collected as part of usual clinical care for research. Objectives: We sought to assess the performance of different assessment methods for obtaining PROs in a pragmatic cluster randomized trial (HomePal study) designed to compare two models of home-based palliative care (HBPC). Design: Descriptive analytics, comparative trends, and psychometric performance of PROs collected in the HomePal study; measures included Edmonton Symptom Assessment System (ESAS), PROMIS-10, and others administered at baseline, 1, and 6 months. Setting/Subjects: HomePal was conducted in the Southern California and Northwest Kaiser Permanente regions in the United States; subjects were patients receiving HBPC and their caregivers. Measurements: We specifically compared ESAS obtained by research staff with those obtained by clinical HBPC nurses at the time of HBPC enrollment. We also compared ESAS completed by patients versus if done or assisted by a caregiver (proxy). Results: We enrolled 3533 patients and had 2205 ESAS measurements that met the criteria for analysis at baseline and 1447 at the one-month follow-up assessment. Research staff-obtained ESAS at admission to HBPC was higher overall (indicating more symptoms) than the clinically collected measure whether symptoms were reported by patients (31.7 ± 15.4 vs. 26.0 ± 13.4) or by proxies (36.9 ± 15.6 vs. 26.5 ± 13.5). These differences persisted with follow-up ESAS measures. Conclusions: We identified significant variability in PRO responses between different surveyors and whether proxy interaction was needed suggesting complex issues around PRO measure performance for pragmatic embedded trials. ClinicalTrials.gov Identifier: NCT03694431.
- 30 March 2022
- Published by SAGE Publications in Journal of Palliative Medicine
- Vol. 25 (4) , 620-627
Performance of Patient-Reported Outcome Measures in a Large Pragmatic Trial of Home-Based Palliative Care (HomePal): Methodological and Practical Considerations for Embedded Patient-Centered Design
Background: The research enterprise has embraced patient centeredness in embedded efficient pragmatic trials, but limited data exist on using patient-reported outcomes (PROs) collected as part of usual clinical care for research. Objectives: We sought to assess the performance of different assessment methods for obtaining PROs in a pragmatic cluster randomized trial (HomePal study) designed to compare two models of home-based palliative care (HBPC). Design: Descriptive analytics, comparative trends, and psychometric performance of PROs collected in the HomePal study; measures included Edmonton Symptom Assessment System (ESAS), PROMIS-10, and others administered at baseline, 1, and 6 months. Setting/Subjects: HomePal was conducted in the Southern California and Northwest Kaiser Permanente regions in the United States; subjects were patients receiving HBPC and their caregivers. Measurements: We specifically compared ESAS obtained by research staff with those obtained by clinical HBPC nurses at the time of HBPC enrollment. We also compared ESAS completed by patients versus if done or assisted by a caregiver (proxy). Results: We enrolled 3533 patients and had 2205 ESAS measurements that met the criteria for analysis at baseline and 1447 at the one-month follow-up assessment. Research staff-obtained ESAS at admission to HBPC was higher overall (indicating more symptoms) than the clinically collected measure whether symptoms were reported by patients (31.7 ± 15.4 vs. 26.0 ± 13.4) or by proxies (36.9 ± 15.6 vs. 26.5 ± 13.5). These differences persisted with follow-up ESAS measures. Conclusions: We identified significant variability in PRO responses between different surveyors and whether proxy interaction was needed suggesting complex issues around PRO measure performance for pragmatic embedded trials. ClinicalTrials.gov Identifier: NCT03694431.
- 20 October 2021
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 70 (9) , 2630-2637
Assessing the concurrent validity of days alive and at home metric
Background: Most patients living with serious illness value spending time at home. Emerging data suggest that days alive and at home (DAH) may be a useful metric, however more research is needed. We aimed to assess the concurrent validity of DAH with respect to clinically significant changes in patient‐ and caregiver‐reported outcomes (PROs). Methods: We drew data from a study that compared two models of home‐based palliative care among seriously ill patients and their caregivers in two Kaiser Permanente regions (Southern California and Northwest). We included participants aged 18 years or older ( n = 3533) and corresponding caregivers ( n = 463). We categorized patients and caregivers into three groups based on whether symptom burden (Edmonton Symptom Assessment System, ESAS) or caregiving preparedness (Preparedness for Caregiving Scale, CPS) showed improvements, deterioration, or no change from baseline to 1 month later. We measured DAH across four time windows: 30, 60, 90, and 180 days, after admission to home palliative care. We used two‐way ANOVA to compare DAH across the PRO groups. Results: Adjusted pairwise comparisons showed that DAH was highest for patients whose ESAS scores improved or did not change compared with those with worsening symptoms. Although the mean differences ranged from less than a day to about 3 weeks, none exceeded 0.3 standard deviations. ESAS change scores had weak negative correlations ( r = −0.11 to −0.21) with DAH measures. CPS change scores also showed weak, positive correlations ( r = 0.23–0.24) with DAH measures. Conclusion: DAH measures are associated, albeit weakly, with clinically important improvement or maintenance of patient symptom burden in a diverse, seriously ill population.
- 20 October 2021
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 70 (9) , 2630-2637
Assessing the concurrent validity of days alive and at home metric
Background: Most patients living with serious illness value spending time at home. Emerging data suggest that days alive and at home (DAH) may be a useful metric, however more research is needed. We aimed to assess the concurrent validity of DAH with respect to clinically significant changes in patient‐ and caregiver‐reported outcomes (PROs). Methods: We drew data from a study that compared two models of home‐based palliative care among seriously ill patients and their caregivers in two Kaiser Permanente regions (Southern California and Northwest). We included participants aged 18 years or older ( n = 3533) and corresponding caregivers ( n = 463). We categorized patients and caregivers into three groups based on whether symptom burden (Edmonton Symptom Assessment System, ESAS) or caregiving preparedness (Preparedness for Caregiving Scale, CPS) showed improvements, deterioration, or no change from baseline to 1 month later. We measured DAH across four time windows: 30, 60, 90, and 180 days, after admission to home palliative care. We used two‐way ANOVA to compare DAH across the PRO groups. Results: Adjusted pairwise comparisons showed that DAH was highest for patients whose ESAS scores improved or did not change compared with those with worsening symptoms. Although the mean differences ranged from less than a day to about 3 weeks, none exceeded 0.3 standard deviations. ESAS change scores had weak negative correlations ( r = −0.11 to −0.21) with DAH measures. CPS change scores also showed weak, positive correlations ( r = 0.23–0.24) with DAH measures. Conclusion: DAH measures are associated, albeit weakly, with clinically important improvement or maintenance of patient symptom burden in a diverse, seriously ill population.